Arrowhead Considering Selling Subsidiary Calando to Cash In On Delivery Technology

Although Arrowhead recently merged Calando with another subsidiary that is not focusing on RNAi, a company official indicated that the company would consider once again separating the RNAi and non-RNAi operations to suit the needs of a potential acquirer, if the terms of a deal were right.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.